CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anchor Therapeutics today announced the appointment of Robert Kamen, Ph.D., past President of Abbott Bioresearch Center, to its Board of Directors. Anchor is developing a new class of therapeutic candidates, called pepducins, to allosterically modulate G protein coupled receptors (GPCRs) on the inside surface of the cell membrane, representing a novel approach to this important target class.
